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Abstract We have analysed a family with nine congenital
neutropenia patients in four generations, several of which
we have studied in a long-term follow-up of over 25 years.
The patients were mild to severe neutropenic and suffered
from various recurrent bacterial infections. Mutations in the
genes ELANE, CSF3R and GFI1 have been reported in
patients with autosomal dominant congenital neutropenias.
Using a small-scale linkage analysis with markers around
the ELANE, CSF3R, CSF3 and GFI1 genes, we were able
to determine that the disease segregated with markers
around the ELANE gene. We identified a novel mutation
in the ELANE gene in all of the affected family members
that was not present in any of the healthy family members.
The mutation leads to an A28S missense mutation in the
mature protein. None of these patients developed leukae-
mia. This is the first truly multigenerational family with
mutations in ELANE as unambiguous cause of severe
congenital neutropenia SCN.
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Introduction
Congenital neutropenia is a disorder of myelopoiesis charac-
terised by impaired neutrophil differentiation with maturation
arrest at the promyelocyte stage. Absolute blood neutrophil
counts (ANC) in neutropenia are below 0.5×10
9/l (severe),
0.5–1×10
9/l (moderate) or 1–1.5×10
9/l (mild). A normal
ANC is on average 4×10
9/l. The major clinical problem
associated with neutropenia is recurrence of bacterial
infections.
Several forms of congenital neutropenia can be distin-
guished: autosomal dominant forms such as severe congenital
neutropenia (SCN) [1], cyclic neutropenia [2], myelokathexis
[3], as well as recessive forms like Shwachman–Diamond’s
syndrome [4]. In patients with autosomal dominant SCN,
mutations have been found in three genes: CSF3R,w h i c h
encodes the granulocyte colony-stimulating factor receptor
(G-CSFR); GFI1, which encodes the growth factor indepen-
dent 1 transcriptional repressor (GFI-1); and ELANE (previ-
ously known as ELA2), which encodes neutrophil elastase. In
83 sporadic SCN patients, mutations have been found in
CSF3R [5–17], and at least 32 of these have developed
leukaemia. Mutations in GFI1 in SCN patients have been
described in one father and his two young children [18] while
transient somatic GFI1 m u t a t i o n sw e r ed e t e c t e di nab o yt h a t
also had mosaic tetraploidy [19]. In 141 SCN patients,
mutations have been found in ELANE (mainly missense
mutations in exon 4) [17, 20–35]; 24 of these patients
developed leukaemia. One promoter polymorphism in ELANE
is also thought to contribute to SCN [36, 37]. All mutations in
ELANE, CSFR3 and GFI1 were present heterozygously in the
patients, as new mutations in the sporadic cases, or inherited
in a dominant fashion in the familial cases.
The occurrence of leukaemia in part of the SCN patients
has given rise to doubts as to whether the mutations in
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leukaemic disorder [38]. Only eight small families with
ELANE mutations were found, in which only a parent and
one or two children were affected [20, 23, 32] and the same
ELANE mutation was found in five children fathered by the
same sperm donor [28]. The lack of families or families
with three or more generations affected, or with more
affected branches, has, however, cast doubt on the causal
effect of the mutations. To complicate the picture, six SCN/
leukaemia patients have been found to have mutations in
both the CSF3R and ELANE genes [17, 35, 39].
We have studied a four-generation family with nine
congenital neutropenia patients in which the disease is
inherited in an autosomal dominant fashion. Most of these
patients suffer from recurrent bacterial infections, including
gingivitis in all. Several of the patients have had appendi-
citis; none has developed leukaemia. The granulocyte
counts in these patients qualify them as mild to severe
neutropenic. We performed linkage analysis in the core
family using highly polymorphic genetic markers around
the most likely candidate genes, ELANE, CSF3R, GFI1 and
CSF3. This analysis indicated a clear linkage between the
ELANE gene and the disorder. Sequence analysis revealed a
mutation in exon two: r.169G>T that results in the
substitution of an alanine by a serine at amino acid 28 in
the mature protein (A28S). The mutation is present in all
patients tested but not in healthy family members. This is
the first multigenerational family with mutations in ELANE
as unambiguous cause of SCN.
Materials and methods
Patients
Patient II-6 presented with recurrent infections, such as
mouth ulcers, gingivitis, conjunctivitis and otitis media, and
complaints of arthralgia and chronic fatigue. She had an
adenotonsillectomy at age 6 and jaundice at age 16. She
died 1 year after being diagnosed with a diffuse large B cell
non-Hodgkin’s lymphoma in the brain at the age of 72.
Patient III-1, a 50-year-old male, has had mastoiditis,
leading to a double mastoidectomy in infancy. In addition,
he had otorrhea and repeated skin and mouth infections
(paradontitis, gingivitis), bronchopneumonia and infectious
complications after operation(s). Patient III-3, a 49-year-old
female, had very painful, recurrent mouth ulcers and skin
folliculitis, myalgia and general fatigue. She had a
mastoidectomy at the age of 16 after repeated mastoiditis
and an acute appendicitis led to an appendectomy at the age
of 18. She has further had a bout of severe gastroenteritis at
the age of 28 and several wound infections after operations
and after giving birth. Patient III-5 is a 43-year-old male
with general fatigue, arthralgia and stiff muscles after
exercise. The patient has further had mouth and skin
infections, recurrent upper airway infections in his youth
and had an adenotonsillectomy at the age of 4 and an
appendectomy for an acute appendicitis at age 13. Patient
III-7 is a 38-year-old male who has not suffered from
recurrent infections although small wounds healed only
slowly. Although actively playing sports, he did complain
of fatigue. Patient IV-1 is a 20-year-old woman and patient
IV-4 is a 14-year-old girl with recurrent infections, mainly
mild gingivitis. Patient IV-6 is an 8-year-old boy; he was
given antibiotic prophylaxis and remains as of yet free of
severe infections. Patient I-2 died (committed suicide) at the
age of 75 and is known to have suffered from recurrent
infections although we have not investigated this. No
material was available from this patient.
DNA and RNA isolation
Blood was collected in heparin tubes (Becton Dickinson,
USA). Genomic DNA was isolated from white blood cells
by a salting out method and dissolved in 10 mM Tris and
0.1 mM EDTA, pH 7.5. RNA was isolated using Trizol
(GibcoBRL) according to manufacturer’s instructions and
dissolved in 10 mM Tris and 0.1 mM EDTA, pH 7.5.
Analysis of polymorphic markers
A limited linkage analysis around the ELANE, CSF3R, CSF3
and GFI1 genes was performed with the following markers:
AFMa302yb5, AFMa312zc9 (CSF3), AFM260zg5,
AFM214yc7, AFM077xg (CSF3R), KB9, AFMa310wd9,
D19S814 (ELANE), AFMa205xd5 and AFMa109wh5
(GFI1). Primer sequences are available on request. Primers
were ordered at Biosource Europe, and one of each set was
5′ FAM-labelled. PCRs were typically performed on 50 ng
of genomic DNA in 10 mM Tris-HCl (pH 9.6), 50 mM
NaCl, 2.5 mM MgCl2,2 0 0μg/ml BSA, 200 μMd N T P s ,
10 pmol primers and 0.5 U AmpliTaq® DNA polymerase
(Applied Biosystems) in a total volume of 25 μl. Thirty to
35 cycli were performed with an annealing temperature
varying from 58°C to 65°C. PCR products were analysed on
gel before analysis of 0.1–1 μl of the PCR product diluted in
HiDi formamide and 0.25 μl ROX-400HD size standard
(Applied Biosystems) on an ABI PRISM®3700 DNA
analyzer (Applied Biosystems). Allele sizes of the markers
were analysed using GeneScan 3.5 and Genotyper (Applied
Biosystems) software.
Mutational analysis
Exons 1, 2, 4 and 5 of ELANE and all five exons of CSF3
along with at least 20 bases of flanking intron or UTR were
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request). PCRs were performed on 200 ng of genomic
DNA in 10 mM Tris-HCl (pH 9.6), 50 mM NaCl, 2.5 mM
MgCl2, 200 μg/ml BSA, 200 μM dNTPs, 10 pmol primers
and 0.8 U AmpliTaq DNA polymerase (Applied Biosys-
tems) in a total volume of 50 μl. Amplification was done in
30 cycles with an annealing temperature of 55°C to 60°C
depending on the primer pair. PCR products were analysed
on gel and purified using a QIAquick PCR purification kit
(Qiagen). Products were sequenced using the BigDye
Terminators v 2.0 Cycle Sequencing kit (Applied Biosys-
tems) and an ABI PRISM®3700 DNA analyzer (Applied
Biosystems). To verify the presence/absence of the muta-
tion in the family, exon 2 PCR products were AcyI (Roche)
digested following the manufacturer’s instructions.
RT-PCR
The sequence of exon 3 of ELANE was analysed in RNA
from blood. One microgram of RNAwas reverse-transcribed
in a reaction containing 5 pmol oligo-dT primer, RT buffer
(Invitrogen), 50 μMD T T ,2 5 0μM dNTPs and 24 U RNAsin
(Promega) using 200 U SuperScript
TM reverse transcriptase
(Invitrogen). One microlitre of cDNA was used in a PCR
reaction in 10 mM Tris-HCl (pH 9.6), 50 mM NaCl, 2.5 mM
MgCl2,2 0 0μg/ml BSA, 200 μMd N T P s ,1 0p m o lp r i m e r s
and 0.8 U AmpliTaq DNA polymerase (Applied Biosystems)
in a total volume of 50 μl. Primer sequences are available
upon request. PCR products were analysed on agarose gels.
PCR products were sequenced as described above.
Neutrophil elastase ELISA
Neutrophil elastase levels were measured using an enzyme-
linked immunosorbent assay (ELISA) that detects both free
and α1-anti-trypsin inhibitor complexed neutrophil elas-
tase, with a lower limit of detection of 1.5 ng/ml [40]. The
ELISA is specific for human neutrophil elastase.
α1-Anti-trypsin phenotyping
α1-Anti-trypsin phenotypes were analysed by standard
isoelectric focusing.
LL-37 ELISA
LL-37 in plasma was measured with an ELISA kit (Hycult
Biotechnology, Uden, The Netherlands).
Neutrophil purification and migration
Granulocytes were isolated from heparinized venous blood
as described [41, 42]. Purity was always greater than 95%.
Neutrophil migration was assessed by means of the
FluoroBlok inserts (Falcon; Becton Dickinson). Cells (5×
10
6/ml) were labelled with 1 μM calcein-AM (Molecular
Probes) for 30 min at 37°C, washed twice and resuspended
in N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
buffer at a concentration of 2×10
6/ml. Chemoattractant
solution (platelet-activating factor (PAF), interleukin 8 (IL-
8) and complement 5a (C5a), all at 10 nM) or medium
alone (0.8 ml/well) was placed in a 24-well plate, and 0.3-
ml cell suspension was delivered to the inserts (3-μm pore
size) and placed in the 24-well plate. Cell migration was
assessed by measuring fluorescence in the lower compart-
ment at 2.5-min intervals for 45 min with the HTS7000+
plate reader (Perkin Elmer). Maximal slope of migration
was estimated over a 10-min interval.
Results
Haematology
A pedigree of the family was assembled (Fig. 1). Haemato-
logical data of patients II-2, III-3 and III-6 have been
collected since 1983 and are summarised in Table 1.
Haematological data for most other affected individuals
and some unaffected family members are presented in
Table 1 as well. Based on these data, there is a striking
heterogeneity in the neutropenia in this family. Individuals
III-1, III-3, III-5, IV-4 and IV-6 can be classified as severely
neutropenic. Individual II-6 can be classified as moderately
neutropenic although she has had more often severe (n=8)
than mild episodes (n=5). Individual III-7 can be classified
as mildly neutropenic. Although neutrophil counts varied
over time in these patients, we did not observe a cyclic
effect in neutrophil counts of patient II-6 or III-3 when
followed at 2- to 3-day intervals for several weeks.
Neutrophil development
Neutropenia can result from reduced production of neu-
trophils in the bone marrow or from increased apoptosis in
the blood and/or from increased clearance from the
peripheral tissues. To study the production of neutrophils
in the bone marrow, biopsies were taken from individuals
II-6, III-1, III-3 and III-5 in 1983 and of II-6 and III-3 again
in 2003. The biopsies were analysed with the following
result: In III-1 and III-5, the bone marrow material
contained few cells, and although all cell types were
present, a typical pattern of maturation arrest was observed
of neutrophil precursors at the promyelocyte–myelocyte
stage with a relative increase in eosinophil cells. The bone
marrow from individuals II-6 and III-3 appeared at both
occasions rich in cells with all cell types present but again
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precursors at the promyelocyte–myelocyte stage with a
relative increase in eosinophil cells.
Neutrophil migration and function
In SCN patients, neutrophil migration has been reported to
be decreased [43]. We tested neutrophil function of a severe
patient (III-3) and a mild patient (III-7) by measuring
directed cell motility (chemotaxis) towards neutrophil-
specific stimuli (i.e. C5a, IL-8 or PAF) acting via different
members of the chemotaxin receptor superfamily. In this
test, the neutrophils did not show abnormalities (data not
shown).
Genetic analysis
Since in autosomal dominant-inherited neutropenia muta-
tions have been described in several genes, we decided to
perform a small-scale linkage analysis around the ELANE,
CSF3R, GFI1 and CSF3 genes. The individuals analysed
were II-5, II-6, III-1 to III-5, III-7, III-8 and IV-1 to IV-5.
Only the markers around the ELANE gene followed the
inheritance pattern of the disorder in this family. We
subsequently sequenced all five exons (including at least
20 bases of flanking introns or untranslated regions) from
genomic DNA or RNA of patients II-6, III-3 and IV-1. All
sequences were wild type except for a heterozygous
r.169G>T mutation [44] in exon 2 in the three patients.
Table 1 Haematological data
Average blood counts
(>20years)
Blood counts at last checkup
II-6 III-3 III-7 II-2 II-3 II-7 II-8 III-1 III-5 III-8 IV-1 IV-4 IV-6 IV-7
Leucocytes, in 10
9/l 3.6 3.9 4.8 8.8 6.4 6.7 7 4.1 2.8 8.3 3.2 6.0 3.9 6.0
Eosinophils (%) 6.8 7.6 2.4 5.4 4.2 4.2 5.9 5.6 4.3 2.5 3.5 17.0 3.3 2.0
Basophils (%) 1.6 1.8 0.9 0.8 0.6 0.5 0.9 2.5 2.5 0.2 1.9 1.0 1 0.5
Neutrophils (%) 16 7.3 33 59 60 54 56 0.3 3.4 73 18 6.0 11 54
Lymphocytes (%) 55 60 47 27 22 32 29 58 59 19 58 59 65 32
Monocytes (%) 19 20 14 8.6 13 9.5 8.2 33 31 5.4 18.4 17.0 19 11.6
l.u.c. (%) 5.3 6.0 3.3 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 0.0 N.D. N.D.
Erythrocytes, in 10
12/l 4.2 4.4 4.9 4.1 4.8 4.9 4.7 4.2 5.2 3.4 4.4 4.8 4.3 4.3
Thrombocytes, in 10
9/l 371 299 246 253 239 222 273 220 341 193 262 375 227 N.D.
Neutrophils, in 10
9/l 0.8 0.3 1.6 5.2 3.9 3.6 3.9 0.01 0.09 6 0.6 0.4 0.4 3.2
Patients are indicated in bold; healthy family members are indicated in normal font. Average blood counts were based on 27 measurements for II-6
(in nine of which only leucocytes, erythrocytes and neutrophils were counted), 27 measurements for III-3 and 20 measurements for III-7 (in two of
which only leucocytes, erythrocytes and neutrophils were counted)
l.u.c. large undifferentiated cells, N.D. not determined
I-1 I-2
II-1 II-7 II-2 II-3 II-4 II-8
III-1 III-2 III-3 III-4 III-6 III-7 III-8
IV-1 IV-2 IV-3 IV-4 IV-5 IV-7
II-5 II-6
III-5
IV-6
Fig. 1 The congenital neutrope-
nia family. Solid symbol,
individual affected with con-
genital neutropenia. Open
symbol, unaffected individual.
Hatched symbol, status un-
known. Individuals I-1, I-2, II-1
and II-4 were not available for
genetic analyses
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family was then tested using an AcyI digest on exon 2 PCR
products. In patients II-6, III-1, III-3, III-5, III-7, IV-1, IV-4
and IV-6, the mutation was present heterozygously. All
healthy family members analysed were homozygous for the
wild-type allele. The mutation r.169G>T results in a
substitution of an alanine (A) for a serine (S) at amino acid
28 of the mature protein.
Based on the heterogeneity in presentation of the
patients in this family, ranging from mild to severe
neutropenic, we hypothesised that a variation in another
gene might be modifying the clinical outcome of disease
severity in these patients. We had observed in the small-
scale linkage analysis around ELANE, CSF3R, CSF3 and
GFI1 that the severely affected individuals III-1, III-3 and
III-5 had inherited a different CSF3 haplotype from their
father than the mildly affected III-7. We therefore se-
quenced the CSF3 gene from individuals II-5, II-6, III-1,
III-3, III-5 and III-7. We identified only one variation,
r.555G>A in exon 5, that does not affect the amino acid
sequence since it is in the third base of the codon for a
leucine (CTG) at position 185 in the protein. This variation
was present in the mother (II-6) and III-3 but not in the
other individuals.
α1-Anti-trypsin phenotype
α1-Anti-trypsin is the major serum inhibitor of neutrophil
elastase. Li and Horwitz [21] have shown, using constructs
of various ELANE mutations, that the inhibition by α1-anti-
trypsin remains similar to that observed for the wild type.
However, α1-anti-trypsin deficiency could influence the
disease severity between the various patients in this family,
which ranges from mild to severe. We therefore analysed
the α1-anti-trypsin phenotype in serum from patients III-3
(severe) and III-7 (mild). Both patients were homozygous
for the common M variant that is associated with normal
α1-anti-trypsin levels.
LL-37 analysis
It was recently reported that LL-37 plasma levels can be
used for differential diagnosis of neutropenic disorders
[45]. LL-37 levels were measured in plasma from 14
members of this family and 14 unrelated controls (Table 2).
In healthy family members and controls, the LL-37 levels
ranged from undetectable to 113 ng/ml with an average
value of 18 ng/ml (21 individuals analysed). In the
granulocytopenia patients, the LL-37 levels ranged from
undetectable (in three individuals) to 239 ng/ml with an
average value of 53 ng/ml (seven patients analysed). No
correlation between severity and LL-37 concentrations
was detected.
Response to G-CSF treatment
G-CSF treatment is known to reverse neutropenia in SCN
patients with ELANE mutations. It has, however, been
reported that the very low (<20 ng/ml) neutrophil elastase
in plasma from SCN patients does not improve upon
treatment with G-CSF [46]. Similarly, neutrophil elastase in
neutrophils was also observed not to increase upon G-CSF
treatment [31]. It has been suggested that expression of
granule-associated proteins, such as neutrophil elastase, and
whether G-CSF has any effect on this expression may
depend on the particular ELANE mutation [47]. We
therefore initially administered two different doses of
G-CSF (Neupogen) with 3-week interval to patient III-3
to monitor the effect on neutrophil elastase. We determined
the neutrophil elastase circulating in the plasma just before,
1 day after and 2 days after subcutaneous G-CSF injection.
Before the first G-CSF treatment, circulating neutrophil
elastase level in patient III-3 was 14.3 ng/ml; this increased
to 25.7 ng/ml 1 day after injection of 300 μg G-CSF and to
28.6 ng/ml at 2 days after injection. Three weeks later,
neutrophil elastase levels were 22.5 ng/ml before injection,
which increased to 35.1 ng/ml 1 day after injection with
600 μg G-CSF and to 37.4 ng/ml 2 days after injection. We
also measured neutrophil elastase concentrations twice in
plasma from the mildly neutropenic brother (III-7) who did
not receive G-CSF treatment. In his plasma, an average of
49.4 ng/ml neutrophil elastase was present. In healthy
controls, neutrophil elastase concentration in plasma is
about 300 ng/ml [46].
Patients II-6, III-3 and IV-4 have been receiving 300 μg
G-CSF twice weekly for over 6 years, and patients III-1 and
II-5 have received 300 μg G-CSF twice weekly for 2 years
Table 2 LL-37 concentration in plasma
Neutrophil
count
a
(×10
9/l)
LL-37 in ng/ml
Patient III-1 0.01 <10
Patient III-5 0.09 <10
Patient III-3 0.3 239
Patient IV-1 0.6 24
Patient II-6 0.8 24
Patient III-7 1.6 <10
Patient IV-4 0.4 86
Mean of above 7 patients 0.5 53
c
21 healthy controls N.D.
b <10 to 113 (mean 18)
c
N.D. not determined
aFrom Table 1
bAverage normal neutrophil count is 4×10
9/l
cFor calculating average <10 was set to 0
Ann Hematol (2011) 90:151–158 155without adverse effects. They have remained free of major
infections and have since had neutrophil counts ranging
from 0.6 to 32.8×10
9/l (Table 3). Patients III-7, IV-1 and
IV-6 have not received G-CSF treatment.
Discussion
We investigated a multigenerational family with SCN and
found the cause of the disease to be a mutation in the
ELANE gene. This is the first unambiguous multigenera-
tional family with autosomal dominant inheritance of SCN.
In addition, the inheritance of the disease in this family
proves that the ELANE mutation in this family is not a
result of a pre-leukemic disorder but the cause of the
congenital neutropenia.
ELANE mutations in multigenerational families are
common in cyclic neutropenia but have not been found in
SCN. Thus far, the vast majority of ELANE mutations in
SCN were found in sporadic cases and occasionally a small
nuclear family was found in which the mutation was
present in one parent and one or two children. In two of
the families reported, the parent was found to be mosaic for
the ELANE mutation [23, 38]. In one family, the father was
neutropenic and developed myelodysplasia, but in the
remaining four families, haematological and clinical data
of the parents are not discussed, and it remains unclear
whether these parents are SCN patients [20]. The authors
suggest these familial cases can be either due to dominant
inheritance or the result of a new germline mutation [20]
but have not proceeded to test for mosaicism.
The mutation found in this family leads to a missense
mutation, A28S in the mature protein, that has not been
identified before. A similar mutation (A28T) has been
described in a sporadic patient with SCN [20]. Serine and
threonine are both hydrophilic amino acids that can be
phosphorylated while alanine is a hydrophobic amino acid
that is not phosphorylated. Li and Horwitz have shown, by
expressing constructs of various ELANE mutations in RBL-1
cells, that the A28T mutant protein exerts reduced proteolytic
activity and a dominant negative effect similar to the other
missense mutations tested [21]. The A28S mutation will likely
have a similar effect on the function of neutrophil elastase.
SCN is known to be a heterogeneous disease in which
severity and symptoms can widely vary. Here we show that
also within one family the neutropenia can vary from mild
to severe. We have attempted to identify factors that modify
the disease in this family by analysing variations in other
candidate genes, in α1-anti-trypsin and in LL-37 concen-
tration but have been unable to find an explanation: A
paternal CSF3 haplotype appeared to segregate with severe
neutropenia, but no variation in the paternal CSF3 gene was
found that could account for the phenotype. The mild and
severe patient analysed for α1-anti-trypsin had the same M
phenotype. Finally, LL-37 concentrations were not corre-
lated with disease severity.
In contrast to the results reported by Karlsson et al. [45]
who found LL-37 concentrations to be invariably higher in
controls than in SCN patients, we did not observe this in
our samples. The mean LL-37 concentration was even
higher in our patients than in controls. Six of the 15 patients
in the report by Karlsson et al. had ELANE mutations, and
it is unclear from the report which of these were included in
the LL-37 measurements; in addition, the mutations in the
six patients were different from the mutation in our family.
The difference in LL-37 concentrations between Karlsson’s
SCN patients and our patients may be due to a number of
factors, the most obvious being that we both studied only a
limited number of patients with different mutations that
may not allow generalisations.
Severe neutropenic patients can be treated with G-CSF
to increase the number of neutrophils, reduce the number of
infections and increase survival [48]. Unfortunately, long-
term treatment with G-CSF does result in an increase in the
incidence of leukaemia [49]. It has been suggested in the
past that the increase in leukaemia may be due to the G-
CSF treatment, but it now appears more likely to be due to
increased survival of pre-leukaemic patients [50, 51]. Most
of the patients described here are being treated with G-CSF
and have not suffered from major infections since. No
leukaemia has been reported thus far. One complication that
is likely not related to G-CSF therapy was the development
of a lethal diffuse large B cell non-Hodgkin’s lymphoma in
the brain in patient II-6. Brain lymphomas have not been
reported before in the course of congenital neutropenia, or
as possible side effect of G-CSF treatment.
G-CSF treatment in patients with ELANE mutations does
in general resolve neutropenia but does not always correct
the deficiency in granule-associated proteins that is seen
during neutropenia [31, 46, 47]. This may be dependent on
the type of ELANE mutation in the patient. We observed
that neutrophil elastase concentrations in the plasma did not
Range of blood counts
a
II-6 III-1 III-3 III-5 IV-4
Leucocytes, in 10
9/l 5.0–11.6 6.3–7.4 4.2–12.1 4.0–7.9 5.5–41.7
Neutrophils, in 10
9/l 1.7–7.1 1.7–2.1 0.4–6.6 1.0–3.2 0.8–32.8
Table 3 G-CSF treatment
response
aData are minimum and maxi-
mum from nine (II-6), four (III-1),
14 (III-3), three (III-5) and six
(IV-4) measurements
156 Ann Hematol (2011) 90:151–158drastically increase in a pilot with either a single or a
double dose of G-CSF.
We investigated the first multigenerational family with
SCN and found the cause of the disease to be a mutation in
the ELANE gene. This is the first unambiguous multigen-
erational family with autosomal dominant inheritance of
SCN, and the inheritance of the disease in this family
proves that the ELANE mutation in this family is not a
result of a pre-leukaemic disorder but the cause of the
congenital neutropenia. Between the affected family mem-
bers, heterogeneity exists in severity of the disease, which
ranged from mild to severe. This may indicate the presence
of modifying factors, but we were unable to identify these.
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